Tag: Antibodies
-
Teva v. Lilly: Federal Circuit Limits Amgen by Distinguishing Method-of-Use Claims from Composition Claims
The Federal Circuit’s decision in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, Case No. 24-1094 (Fed. Cir. Apr. 16, 2026), marks one of the most important post-Amgen v. Sanofi patent decisions involving antibody claims and Section 112. In a unanimous opinion authored by Chief Judge Prost, the court reversed a district court judgment…